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Functions of Epstein-Barr virus (EBV)-encoded RNAs (EBERs) were tested in lymphoblastoid cell lines containing EBERmu-
tants of EBV. Binding of EBER1 to ribosomal protein L22 (RPL22) was confirmed. Deletion of EBER1 or EBER2 correlated with
increased levels of cytoplasmic EBV LMP2 RNA and with small effects on specific cellular microRNA (miRNA) levels, but protein
levels of LMP1 and LMP2A were not affected. Wild-type EBV and EBER deletion EBV had approximately equal abilities to infect
immunodeficient mice reconstituted with a human hematopoietic system.
Epstein-Barr virus (EBV)-encoded RNAs (EBERs) are abun-dant viral noncoding RNAs in EBV-transformed lymphoblas-
toid cell lines (LCLs). We previously identified cell genes whose
expression in EBV LCLs correlates with deletion of EBER1 or
EBER2 (1); here, we used LCLs to test various mechanisms that
have been proposed for EBER function.
Binding of EBER1 to ribosomal protein L22 (RPL22) in LCLs
is confirmed, but no effect of EBER1 on p53 protein level was
detected. EBER1 can bind to RPL22 (2), and studies on RPL22
knockout mice (3, 4) showed a p53-dependent defect in pro-B
cells (4). The effect is thought to involve RPL22 binding to p53
mRNA, reducing translation of p53 (5). It is possible that EBER1
could modulate this pathway, although EBV infects mature B
cells, in which the RPL22 phenotype was previously reported to be
absent (4). We confirmed binding of RPL22 to endogenous
EBER1 in extracts of an LCL (Fig. 1A). The p53 protein level was
determined by Western blotting in LCLs, and the response to
treatment using cisplatin, which stabilizes p53, was also tested.
There was no significant difference in the p53 levels or responses
between the cells with andwithout EBER1 expression (Fig. 1B), so
EBER1 does not appear to affect p53 expression in LCLs.
Effect of EBERs on cellular miRNAs. To determine whether
the EBERs might affect cellular microRNAs (miRNAs), we used
LCLs containing wild-type (wt) B95-8 bacterial artificial chromo-
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FIG 1 (A) Flag-tagged RPL22 (L22) or negative-control (C) (Flag-tagged
Schlafen) proteins were expressed by Neon transfection in LCL cells con-
taining B95-8 BAC EBV. Cell extracts were incubated with M2 anti-FLAG
antibody (Sigma-Aldrich) bound to protein G Sepharose beads. RNA was
extracted from the beads (using immunoprecipitation [IP]) and the un-
bound supernatant (Sup) and tested for EBER by Northern blotting. (B)
Cells from three independent EBER1 LCLs (light gray bars) or wt EBV
LCLs (WT; black bars) were treated with 20g/ml cisplatin (C) in triplicate
or were left untreated (U) as a control. For each sample, 2 ml of cell
suspension (at 2.5  105 viable cells/ml, determined by trypan blue exclu-
sion) was set up per well in 6-well plates with or without cisplatin as
indicated. The number of viable cells (excluding trypan blue) was deter-
mined after 16 h, and p53 protein was detected by Western blotting of cell
extracts made at the same time point. DO1 antibody (Santa Cruz) was used
for detection of p53 by Western blotting. Actin was used as a loading
control on the Western blots.
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some (BAC) EBV, EBER1 or EBER2 deletion mutants, or rever-
tant viruses. Total RNA was isolated from each LCL, and small
RNAs were used to generate Illumina sequencing libraries (6).
Appropriate expression of the EBER1 and EBER2 RNAs was con-
firmed by Northern blotting (Fig. 2A).
Sequencing detected miRNAs from all 8 EBV B95-8 pre-
miRNAs and 491mature human cellularmiRNAs. Sequence reads
are available at NCBI BioProject PRJNA287267. The general pat-
tern of viral and cellular miRNA expression was comparable to
that observed previously in EBV B95-8 LCLs (6); miR-155, miR-
146a/b, and miRNAs encoded within the miR-17/92 cluster were
highly abundant, and the EBV miRNAs constituted12% of the
population (see Table S1 in the supplemental material). As in
prior studies (6–8), we found no evidence for production of dis-
crete miRNA-like products from the EBERs.
Sixteen miRNAs (P value  0.01; 2  log fold change
[logFC]  2) had expression levels altered in response to the
deletion of EBER1, while 11 miRNAs had expression levels that
were changed in response to EBER2 deletion (see Table S2 in
the supplemental material). There were significant differences
in the levels of miR-340-3p, miR-340-5p, miR-190a-3p, miR-
190a-5p, and miR-33a-5p in EBER1-deleted LCLs compared
to wt LCLs (Fig. 2B to D; see also Table S2). Only small changes
in levels of expression of miRNAs (such as miR-199a) were
observed in EBER2-deleted LCLs (Fig. 2D; see also Table
S2). Both the 3p and 5p miRNAs for miR-190 and miR-340
were affected by the deletion of EBER1, indicating that the pro-
moters driving expression of the primary miRNA transcripts
were affected (Fig. 2B), consistent with a recent report on
miR-190 (9).
The results of additional TaqMan quantitative reverse tran-
scription-PCR (qRT-PCR) assays performed on RNA from inde-
pendently established LCLs supported the idea of expression of
bothmiR-340-5p and -3p correlatingwith EBER1 expression (Fig.
2E), but the fold change level was lower in this assay. Since the
levels of these miRNAs are all quite low in LCLs (Fig. 2B; see also
FIG 2 (A) EBER1 and EBER2 expression in the wt and EBER-deleted LCLs used for deep sequencing analysis was confirmed by Northern blotting (1). A 0.5-g
volume of total RNA was used per well. (B) Normalized miRNA read counts for miR-190a andmiR-340 in EBER1-deleted (delE1) LCLs compared to wild-type
(wt) and EBER1 revertant (E1R) LCLs. “A” and “B” denote the two individual LCLs analyzed for each condition. About 10 million sequencing reads were
obtained for each LCL library. Readswere processed as described previously (6) using scripts from the fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). To
determinemiRNA levels, reads were aligned to the human (HG19) and EBVB95-8 genomes and annotated according tomirbase v21 (http://www.mirbase.org/).
To determine miRNA expression levels, miRNA read counts were obtained using the quantifier module of miRDeep2 (14) (see Table S1 in the supplemental
material). To identify differentially expressed (DE) miRNAs, miRNA read counts were analyzed by edgeR using trimmed mean of M (TMM) values for
normalization (15, 16). For inclusion in the analysis, a minimum of 40 reads per miRNA in at least one of the 10 LCL libraries was required. DE miRNAs with
a LogFC P value of0.05 are reported in Table S2. (C) Normalized miRNA read counts for miR-33a in EBER1-deleted LCLs. (D) Summary of log fold changes
(logFC) of selected cellular miRNAs showing significant changes correlating with EBER1 or EBER2 expression as determined by deep sequencing and edgeR
analysis. (E) Relative levels of miR-340-5p andmiR-340-3p determined by TaqMan qRT-PCR assays in LCLs. The expression levels of miRNAs were normalized
toRNU48. The values representmeans	 standard errors (SE) of the results of analysis of 6 independent samples per EBV type (5 in the case of EBER1 revertants).
Thewild-type expression levels were set to 1 for eachmiRNA,whereas the levels of other sampleswere expressed relative to thewild-type level. Each cDNA sample
was analyzed in triplicate.
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FIG 3 Cytoplasmic RNA from two LCLs each for EBV wild type (WT), deletion of EBER1 (E1), revertant (E1R), and deletion of EBER2 (E2) or revertant
(E2R) was used for cDNA synthesis performed with either random primers (A) or oligo(dT) (B) using a ProtoScript First Strand cDNA synthesis kit (New
England BioLabs). Quantitative PCR (Q-PCR) performed with the same primers as those described in reference 10 was then used in duplicate assays to measure
the levels of RNA for LMP1, LMP2A, and LMP2B, using GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as a reference. The threshold cycle (2CT)
method of comparative PCR (17) was used to analyze the results, expressed as fold change relative to the E1R LMP1 value. (C) Radioimmunoprecipitation assay
(RIPA) lysates were prepared from LCLs, and equal amounts of cell protein were analyzed byWestern immunoblotting. Membranes were probed with a 1/1,000
dilution of anti-LMP2A (Abcam; 14B7), a 1/500 dilution of anti-LMP1 (Dako; clone CS.1-4), or a 1/5,000 dilution of anti-
 actin (Sigma; AC-74). Secondary
antibodies were horseradish peroxidase-conjugated sheep anti-mouse immunoglobulin (GE Healthcare) or horseradish peroxidase-conjugated rabbit anti-rat
immunoglobulin (Sigma). Bound immunocomplexes were detected by enhanced chemiluminescence (GE Healthcare).
FIG 4 (A) Newborn HLA-A*0201 transgenic NOD/LtSz-Scid IL2Rnull (NSG-A2tg) mice were irradiated and injected intrahepatically with CD34 human
hematopoietic progenitor cells as described previously (18). The reconstitution of human immune system components in the peripheral blood was analyzed
prior to the beginning of experiments (normally 12 weeks after engraftment). Groups ofmice were infected with 105 infectious units of virus andmonitored over
a 4-to-8-week period in three experiments, each using different groups of reconstitutedmice. EBV loads in spleen and whole blood were quantified 4 weeks after
infection for wild-type (EBV wt), EBER1-deficient (E1), EBER2-deficient (E2), EBER1-and-EBER2-deficient (E12), and EBER2 revertant (E2rev) viruses.
(B) CD8 T cell expansion was slightly elevated in the absence of EBER1. The T cell ratio of CD8 to CD4 was assessed by flow cytometry after 4 weeks of
infectionwith the same viruses as described for panel A. The composition of blood and spleen samples from the humanizedmice was analyzed using anti-human
CD45 (HI30; Biolegend), anti-CD3 (UCHT1; Biolegend), anti-CD4 (RPA T4; Biolegend), anti-CD8 (SK1; Biolegend), anti-HLA-DR (L243; Biolegend), anti-
CD45RO (UCHL1; BD Pharmingen), and anti-CD19 (HIB19; BD Pharmingen). Spleens were mechanically disrupted and filtered through a 70-m-pore-size
cell strainer. Erythrocytes were lysed inwhole blood or in spleen suspensions usingNH4Cl. Cell suspensionswere stainedwith the indicated antibodies for 15min
at 4°C and washed. Statistical analysis for all mouse experiments used two-tailed t tests. A P value of0.05 was considered statistically significant.
Epstein-Barr Virus EBER RNAs
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Table S1 in the supplemental material), we conclude that it is
unlikely that the main function of EBERs in LCLs is to alter levels
of cellularmiRNAs but also that the changes inmiRNA expression
may contribute to the effects on cellularmRNA levels in LCLs that
we reported previously (1).
Deletion of EBER1 or EBER2 correlates with raised levels of
LMP2 RNAs in LCLs. EBER2 was recently shown to bind PAX5
and to promote PAX5 binding to the terminal repeat region of the
EBV genome (10). Knockdown of EBER2 by small interfering
(siRNA) caused a 50% increase in LMP1 and LMP2 RNA levels
(10). Using quantitative PCR (qPCR) with the same primers on
cytoplasmic RNA, we did not observe any significant difference
between the EBER2 deletion LCLs and wild-type EBV LCLs in the
levels of LMP1 RNA, but LMP2A and LMP2B RNA levels were
2-fold to 3-fold higher when either EBER1 or EBER2 was deleted
(Fig. 3A andB), particularly when the cDNA synthesis was primed
with oligo(dT) (Fig. 3B). LMP1 and LMP2A protein levels are
quite variable in LCLs (Fig. 3C), and there was no apparent cor-
relation with EBER expression. Our results thus provide some sup-
port for the idea of EBER2 tending to reduce the level of LMP2 RNA
(10), but the specific binding of EBER2 toPAX5 and associationwith
the terminal repeat may not mediate the LMP2 RNA effect that we
observed, since therewas an increase in the level of LMP2RNAwhen
either EBER1 or EBER2was deleted. The focus of the previous study
on EBER2 meant that an effect of EBER1 deletion on LMP2 RNA
levels was not tested in those experiments (10).
Infection of mice with a human hematopoietic system with
EBV lacking EBER genes. Using the EBER mutant EBV strains,
we tested whether EBERs affect establishment of EBV infection in
NSG mice with a humanized hematopoietic system (11). In three
separate experiments involving a total of 44 correctly reconsti-
tuted mice, there was no significant difference between the fre-
quencies of infection detected in the blood or in the spleen with
deletion of either or both EBER genes from the virus genome.
Spleen and blood viral loads are shown in Fig. 4A.
Analyzing parameters of cell-mediated immune responses to-
ward the viral infections, we observed a tendency toward more-
pronounced CD8 T cell expansion in the infection with EBER1-
deficient viruses (Fig. 4B). However, this tendency was primarily
observed in one experiment andwas not present in infectionswith
an EBV deficient in both EBERs.
Most studies have focused on cell-intrinsic functions for EBERs,
but EBERs have also been reported to be released from cells (12) and
in exosomes (13), potentially affecting immune or inflammatory re-
sponses (M. Pegtel, personal communication). Most likely, physio-
logical phenotypes for the EBERs will be revealed by in vivo infection
challenged by normal immune responses. We have now shown that
deletion of EBERs does not prevent infection of humanized mice,
making this type of analysis possible.
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